ALPS Medical Breakthroughs ETF – AMEX:SBIO

ALPS Medical Breakthroughs ETF stock price today

$33.93
+0.21
+0.62%

ALPS Medical Breakthroughs ETF stock price monthly change

-8.64%
month

ALPS Medical Breakthroughs ETF stock price quarterly change

-8.64%
quarter

ALPS Medical Breakthroughs ETF stock price yearly change

+0.62%
year

ALPS Medical Breakthroughs ETF key metrics

Market Cap
121.67M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
N/A
Revenue
N/A
EBITDA
N/A
Income
N/A
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

ALPS Medical Breakthroughs ETF stock price history

ALPS Medical Breakthroughs ETF stock forecast

ALPS Medical Breakthroughs ETF financial statements

ALPS Medical Breakthroughs ETF other data

Saturday, 14 December 2024
seekingalpha.com
Monday, 2 December 2024
etftrends.com
Thursday, 21 November 2024
etftrends.com
Wednesday, 13 November 2024
etftrends.com
Tuesday, 12 November 2024
etftrends.com
Tuesday, 22 October 2024
etftrends.com
Thursday, 10 October 2024
businesswire.com
Friday, 27 September 2024
etftrends.com
Wednesday, 4 September 2024
etftrends.com
Tuesday, 3 September 2024
etftrends.com
Thursday, 29 August 2024
etftrends.com
Monday, 19 August 2024
etftrends.com
Friday, 26 July 2024
zacks.com
Friday, 19 July 2024
etftrends.com
zacks.com
Thursday, 18 July 2024
zacks.com
etftrends.com
Friday, 14 June 2024
etftrends.com
Tuesday, 7 May 2024
ETF Trends
Tuesday, 6 February 2024
ETF Trends
Wednesday, 17 January 2024
Zacks Investment Research
Monday, 8 January 2024
ETF Trends
Friday, 29 December 2023
Zacks Investment Research
Thursday, 28 December 2023
ETF Trends
Thursday, 14 December 2023
ETF Trends
Monday, 11 December 2023
Zacks Investment Research
Thursday, 7 December 2023
ETF Trends
Tuesday, 31 October 2023
ETF Trends
Monday, 30 October 2023
Zacks Investment Research
Thursday, 29 June 2023
Zacks Investment Research
  • What's the price of ALPS Medical Breakthroughs ETF stock today?

    One share of ALPS Medical Breakthroughs ETF stock can currently be purchased for approximately $33.93.

  • When is ALPS Medical Breakthroughs ETF's next earnings date?

    Unfortunately, ALPS Medical Breakthroughs ETF's (SBIO) next earnings date is currently unknown.

  • Does ALPS Medical Breakthroughs ETF pay dividends?

    No, ALPS Medical Breakthroughs ETF does not pay dividends.

  • How much money does ALPS Medical Breakthroughs ETF make?

    ALPS Medical Breakthroughs ETF has a market capitalization of 121.67M.

  • What is ALPS Medical Breakthroughs ETF's stock symbol?

    ALPS Medical Breakthroughs ETF is traded on the AMEX under the ticker symbol "SBIO".

  • What is ALPS Medical Breakthroughs ETF's primary industry?

    Company operates in the Financial Services sector and Asset Management industry.

  • How do i buy shares of ALPS Medical Breakthroughs ETF?

    Shares of ALPS Medical Breakthroughs ETF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When ALPS Medical Breakthroughs ETF went public?

    ALPS Medical Breakthroughs ETF is publicly traded company for more then 10 years since IPO on 31 Dec 2014.

ALPS Medical Breakthroughs ETF company profile:

ALPS Medical Breakthroughs ETF

Exchange:

AMEX

Full time employees:

0

Industry:

Asset Management

Sector:

Financial Services

The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.


,

CIK: 0001414040
ISIN: US00162Q5936
CUSIP: 00162Q593